NASDAQ: TLPHTalphera Inc Stock
$0.99-0.05 (-4.81%)
Updated Apr 19, 2024
TLPH Price
$0.99
Fair Value Price
-$0.26
Market Cap
$16.80M
52 Week Low
$0.43
52 Week High
$1.61
P/E
-0.77x
P/B
1.19x
P/S
16.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$651.00k
Earnings
-$18.40M
Gross Margin
100%
Operating Margin
-2,805.38%
Profit Margin
-2,826%
Debt to Equity
0.45
Operating Cash Flow
-$17M
Beta
1.19
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TLPH Overview
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TLPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLPH ($0.99) is overvalued by 476.92% relative to our estimate of its Fair Value price of -$0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TLPH ($0.99) is not significantly undervalued (476.92%) relative to our estimate of its Fair Value price of -$0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TLPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TLPH due diligence checks available for Premium users.
Be the first to know about important TLPH news, forecast changes, insider trades & much more!
TLPH News
Valuation
TLPH fair value
Fair Value of TLPH stock based on Discounted Cash Flow (DCF)
Price
$0.99
Fair Value
-$0.26
Undervalued by
476.92%
TLPH ($0.99) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TLPH ($0.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TLPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TLPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.77x
Industry
46.11x
Market
40.51x
TLPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.19x
Industry
2.03x
TLPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLPH's financial health
Profit margin
Revenue
$281.0k
Net Income
-$4.5M
Profit Margin
-1,607.5%
TLPH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TLPH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.4M
Liabilities
$6.3M
Debt to equity
0.45
TLPH's short-term assets ($11.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLPH's short-term assets ($11.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
-$3.7M
Financing
-$68.0k
TLPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLPH vs Pharmaceutical Stocks
Talphera Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.